BHC(SH:600721) Zhong Zheng Wang·2026-01-06 13:09Core Viewpoint - Baihua Pharmaceutical (600721) announced the termination of the planned change in control due to a lack of consensus with the counterparties, and the company's stock will resume trading on January 7, 2026 [1][2]. Group 1: Control Change Announcement - The controlling shareholders and actual controllers, Mi Naqi, Mi Enhua, and Yang Xiaoling, decided to terminate the control change due to disagreements on significant matters [1]. - The company had previously announced a potential share transfer that could lead to a change in control, prompting a temporary suspension of trading to ensure fair information disclosure and protect investor interests [1]. Group 2: Business Operations and Financial Performance - The company stated that the termination of the control change will not have a significant adverse impact on its operational performance and financial status [2]. - Baihua Pharmaceutical's main business includes early drug discovery, CMC development, clinical trials, registration applications, and various pharmaceutical services, providing comprehensive outsourcing and technology transfer services [2]. - For the first three quarters of 2025, the company reported revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year growth of 36.41% [3].